DBVT

DBV Technologies S.A. Sponsored ADR (DBVT) | Rumor.io

DBV Technologies

DBVT

Attention (50-day avg)0%

Attention rank (50-day avg)#3,248

Bullish sentiment (50-day avg)100%

Price to earnings ratio-2.21

Market capitalization731.6M

Earnings per share-3.5

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-146.9M

Social

What share of all stock conversation is about DBVT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 18

DBV Technologies S.A. (DBVT) has a dilution agreement for 11.9 million ADSs at $4.55, effective upon positive phase 3 results.
Analysts estimate the company's peak sales at $4 billion, valuing the company at $4 billion even with dilution, making a target price of $18 per share attractive.
DBVT has seen a 25.42% market increase to $22.55 following a SEC filing, with a two-way flow and balanced structure in its stock.

Generated by AI

Sentiment

Of the messages about DBVT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	86.82% +10.25
Bearish	—	—	—	13.18% -10.25

Bullish· Dec 17

DBV Technologies S.A. has solid management and is a great company to invest in.
The stock's price target is already set at $30, indicating a high level of optimism among analysts.
The company's peanut allergy patch has finally found clinical success, sending shares soaring by 37.1% pre-market.

Bearish· Mar 28

DBV Technologies S.A.'s financing deal, while saving the company as a business, has crushed current shareholders and will dilute their shares by 25-75%.
The company's investor call is seen as a "dog and pony show" and is expected to lead to further price drops, with some predicting a 20%+ decline after the 8K filing.
The new financing terms may result in DBVT never reaching its current high again, due to the potential for significant dilution of shareholder value.

Generated by AI

Topics

Of the messages about DBVT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	72.92%
Analysts	—	—	—	11.4%
Controversies	—	—	—	4.63%
Earnings	—	—	—	0.59%
Macro	—	—	—	6.18%
Technical Analysis	—	—	—	4.28%

Earnings· Mar 12

DBVT earnings are upcoming, indicating a pending release of the company's financial performance data.
The timing of the earnings release is not specified, but it is expected to provide insight into the company's financial health.
The focus on DBVT's earnings suggests that investors are anticipating significant information about the company's performance.

Analysts· Dec 20

DBV Technologies S.A. ($DBVT) received several downgrades from analysts, including BofA/Merrill, Stifel, Barclays, and Jefferies.
BofA/Merrill downgraded DBV Technologies to Underperform with a price target of $8, while Jefferies downgraded the company to Hold with a price target of $8.
JMP Securities reiterated a Market Outperform rating for DBV Technologies with a price target of $20.

Announcements· Dec 17

DBV Technologies S.A. (DBVT) shares surged +41% premarket on positive Phase 3 data for its VIASKIN Peanut patch, a treatment for peanut allergy in children aged 4-7 years.
The VITESSE trial achieved a 46.6% response rate vs 14.8% placebo after 12 months, exceeding expectations.
DBVT is on track to submit a BLA for the 4-7 year old age group in H1 2026, with enrollment exceeding the target at 654 children.

Technical Analysis· Nov 2

DBVT has shown a pattern of sell-off at market open, attempting to bounce to pre-market highs, and getting rejected and fading all day, with the 2.3 level being a key break.
The stock has potential to squeeze if it breaks above 2.50-2.60 and fills the gap, with some analysts expecting a run to 3 or even 4.
A double bottom pattern has formed, with the break of 2.52 potentially sending the stock to a target of 2.98 or beyond.

Generated by AI

Community

Of the messages about DBVT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	49.61%
Newcomers	—	—	0%	50.39%

Regulars· Dec 17

DBV Technologies announced positive topline results from the Phase 3 VITESSE trial of VIASKIN Peanut Patch in children aged 4-7 years, with enrollment exceeding the target at 654 children.
The BLA submission for 4–7-year-olds is on track for the first half of 2026.
The Phase 3 VITESSE trial results are a key milestone in the development of VIASKIN Peanut Patch, a treatment for peanut allergies in children.

Newcomers· Dec 17

The company's technology for treating tree allergies could lead to significant profits, with a potential market size of billions.
The stock's price may be affected by the upcoming 75% dilution of shares due to warrant holders, as well as management's aggressive use of the ATM.
A potential takeover by Roche could be beneficial, given the company's launch of a food allergy treatment and the fact that Xolair is not approved for 1-7 year olds.

Generated by AI

News

Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and TransMedics Group (TMDX)

Detailed price information for Transmedics Group Inc (TMDX-Q) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

Cantor Fitzgerald reiterates DBV Technologies stock rating at overweight

19d agoInvesting.com

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026(Article 223-16 of the Gene...

27d agomarkets.businessinsider.com

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market Program established on September 1, 2025 and included in a new registration statement and accompanying prospectus filed on July 27, 2026, (the “A

2mo agoYahoo Finance

DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap

2mo agoSeeking Alpha

DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside (NASDAQ:DBVT)

2mo agoSeeking Alpha

Also Discussed

Investors talking about DBVT also mention

#	Name	Attention
1	AnaptysBio, Inc.ANAB	0%0
2	GNFT - Genfit S.A.	——
3	Inventiva S.A. American Depositary ReceiptIVA	0%-0.01
4	Cellectis S.A. ADRCLLS	0%0
5	Galapagos NV American Depositary ReceiptGLPG	0%0
6	AC Immune SAACIU	0%0
7	PRTK - Paratek Pharmaceuticals, Inc.	——
8	Summit Midstream Partners LPSMLP	0%0
9	ITCI - Intra-Cellular Therapies, Inc.	——
10	eXoZymes Inc.EXOZ	0%0

DBV Technologies S.A. Sponsored ADR

Healthcare
Biotechnology

DBV Technologies S.A. Sponsored ADR is a France-based biopharmaceutical company focused on epicutaneous immunotherapy, a skin-based approach designed to deliver biologically active compounds through intact skin. The company’s core platform, Viaskin, supports the development of patch-based therapies for food allergies and other immune-mediated conditions. DBV Technologies works at the intersection of immunology and advanced drug delivery, with products and programs centered on non-invasive treatment methods for patients with allergic diseases. Its sponsored ADR gives investors U.S. market access to the company’s ordinary shares while representing the underlying business in the global healthcare sector. The company is headquartered in Châtillon, France, and remains focused on research, development, and commercialization efforts within specialty biopharmaceuticals.

Website

Location

BAtiment IRO

Châtillon, 92320

France

Social

What share of all stock conversation is about DBVT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 18

DBV Technologies S.A. (DBVT) has a dilution agreement for 11.9 million ADSs at $4.55, effective upon positive phase 3 results.
Analysts estimate the company's peak sales at $4 billion, valuing the company at $4 billion even with dilution, making a target price of $18 per share attractive.
DBVT has seen a 25.42% market increase to $22.55 following a SEC filing, with a two-way flow and balanced structure in its stock.

Generated by AI

Sentiment

Of the messages about DBVT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	86.82% +10.25
Bearish	—	—	—	13.18% -10.25

Bullish· Dec 17

DBV Technologies S.A. has solid management and is a great company to invest in.
The stock's price target is already set at $30, indicating a high level of optimism among analysts.
The company's peanut allergy patch has finally found clinical success, sending shares soaring by 37.1% pre-market.

Bearish· Mar 28

DBV Technologies S.A.'s financing deal, while saving the company as a business, has crushed current shareholders and will dilute their shares by 25-75%.
The company's investor call is seen as a "dog and pony show" and is expected to lead to further price drops, with some predicting a 20%+ decline after the 8K filing.
The new financing terms may result in DBVT never reaching its current high again, due to the potential for significant dilution of shareholder value.

Generated by AI

Topics

Of the messages about DBVT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	72.92%
Analysts	—	—	—	11.4%
Controversies	—	—	—	4.63%
Earnings	—	—	—	0.59%
Macro	—	—	—	6.18%
Technical Analysis	—	—	—	4.28%

Earnings· Mar 12

DBVT earnings are upcoming, indicating a pending release of the company's financial performance data.
The timing of the earnings release is not specified, but it is expected to provide insight into the company's financial health.
The focus on DBVT's earnings suggests that investors are anticipating significant information about the company's performance.

Analysts· Dec 20

DBV Technologies S.A. ($DBVT) received several downgrades from analysts, including BofA/Merrill, Stifel, Barclays, and Jefferies.
BofA/Merrill downgraded DBV Technologies to Underperform with a price target of $8, while Jefferies downgraded the company to Hold with a price target of $8.
JMP Securities reiterated a Market Outperform rating for DBV Technologies with a price target of $20.

Announcements· Dec 17

DBV Technologies S.A. (DBVT) shares surged +41% premarket on positive Phase 3 data for its VIASKIN Peanut patch, a treatment for peanut allergy in children aged 4-7 years.
The VITESSE trial achieved a 46.6% response rate vs 14.8% placebo after 12 months, exceeding expectations.
DBVT is on track to submit a BLA for the 4-7 year old age group in H1 2026, with enrollment exceeding the target at 654 children.

Technical Analysis· Nov 2

DBVT has shown a pattern of sell-off at market open, attempting to bounce to pre-market highs, and getting rejected and fading all day, with the 2.3 level being a key break.
The stock has potential to squeeze if it breaks above 2.50-2.60 and fills the gap, with some analysts expecting a run to 3 or even 4.
A double bottom pattern has formed, with the break of 2.52 potentially sending the stock to a target of 2.98 or beyond.

Generated by AI

Community

Of the messages about DBVT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	49.61%
Newcomers	—	—	0%	50.39%

Regulars· Dec 17

DBV Technologies announced positive topline results from the Phase 3 VITESSE trial of VIASKIN Peanut Patch in children aged 4-7 years, with enrollment exceeding the target at 654 children.
The BLA submission for 4–7-year-olds is on track for the first half of 2026.
The Phase 3 VITESSE trial results are a key milestone in the development of VIASKIN Peanut Patch, a treatment for peanut allergies in children.

Newcomers· Dec 17

The company's technology for treating tree allergies could lead to significant profits, with a potential market size of billions.
The stock's price may be affected by the upcoming 75% dilution of shares due to warrant holders, as well as management's aggressive use of the ATM.
A potential takeover by Roche could be beneficial, given the company's launch of a food allergy treatment and the fact that Xolair is not approved for 1-7 year olds.

Generated by AI

DBV Technologies

Social

Dec 18

Bullish· Dec 17

Bearish· Mar 28

Earnings· Mar 12

Analysts· Dec 20

Announcements· Dec 17

Technical Analysis· Nov 2

Regulars· Dec 17

Newcomers· Dec 17

Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and TransMedics Group (TMDX)

Cantor Fitzgerald reiterates DBV Technologies stock rating at overweight

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap

DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside (NASDAQ:DBVT)

Also Discussed

DBV Technologies S.A. Sponsored ADR

Company Information

Location

Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and TransMedics Group (TMDX)

Cantor Fitzgerald reiterates DBV Technologies stock rating at overweight

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap

DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside (NASDAQ:DBVT)

Also Discussed

Social

Dec 18

Bullish· Dec 17

Bearish· Mar 28

Earnings· Mar 12

Analysts· Dec 20

Announcements· Dec 17

Technical Analysis· Nov 2

Regulars· Dec 17

Newcomers· Dec 17